Plasminogen activator inhibitor-1 in cancer research
Plasminogen activator inhibitor-1 in cancer research
复制标题
DOI：
10.1016/j.biopha.2018.05.119
复制
发表时间：
2018-09-01
影响因子：
7.5
通讯作者：
Sun, Li
中科院分区：
文献类型：
--
作者：
Li, Sijing;Wei, Xiaohui;Sun, Li
[尽管作为尿激酶（uPA）的主要抑制剂，矛盾的是]基于大量临床数据库分析，纤溶酶原激活物抑制剂-1 （PAI-1）已被证实在各种类型的肿瘤活检组织或血浆中与对照组相比高表达，更重要的是，PAI-1单独或与uPA联合已被确定为某些癌症类型的疾病进展和复发的预后因素。尤其是乳腺癌。PAI-1除了在细胞粘附、迁移和侵袭中发挥重要作用外，还可诱导肿瘤血管化，从而促进细胞播散和肿瘤转移。此外，有许多促瘤因子参与调节PAI-1的表达和活性，这将加强PAI-1的促瘤作用。毫无疑问，PAI-1可能是特异性癌症治疗干预的一个有希望的靶点。事实上，一些PAI-1抑制剂目前正在癌症治疗中进行评估，未来可能会发展成为新的抗肿瘤药物。
[Despite as a major inhibitor of urokinase (uPA), paradoxically,] Plasminogen activator inhibitor-1 (PAI-1) has been validated to be highly expressed in various types of tumor biopsy tissues or plasma compared with controls based on huge clinical data bases analysis, more importantly, PAI-1 alone or in conjunction with uPA have been identified as prognostic for disease progression and relapse in certain cancer types. particularly in breast cancer. In addition to play important roles in cell adhesion, migration and invasion, PAI-1 has been reported to induce tumor vascularization and thus promote cell dissemination and tumor metastasis. Furthermore, there are many tumor promoting factors involved in the modulation of PAI-1 expression and activity, which will strengthen the pro-tumorigenic roles of PAI-1. Undoubtedly, PAI-1 may be a promising target for therapeutic intervention of specific cancer treatment. In fact, some PAI-1 inhibitors are currently being evaluated in cancer therapy, which may be developed to new antitumor agents in the future.